Latest Content

Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.

The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.

In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.

Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.

At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.

EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence planning must start earlier.

Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management service.

GEODIS' David Frouin explains why securing the lane outranks sustainability and why full corridor models are the cold chain trend to watch.

Agentic AI is moving biopharma from tools that inform decisions to systems that execute them, reshaping discovery, clinical trials, commercial launch and regulatory work.

At LogiPharma USA 2026, Freehand's Nitin Jayakrishnan explains why AI and the people supply chain will shape pharma supply strategy.

At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal discusses reusable shippers, PCM innovation and AI's role in cold chain risk.

Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.